BamSEC and AlphaSense Join Forces
Learn More

Recursion Pharmaceuticals Inc.

NASDAQ: RXRX    
Share price (12/20/24): $6.03    
Market cap (12/20/24): $1.728 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from DEFA14A 10 pages Institutional Shareholder Irrevocable Undertaking
12/34/56
EX-10.1
from 8-K 10 pages Institutional Shareholder Irrevocable Undertaking
12/34/56
EX-10.3
from 8-K 12 pages Individual Shareholder Irrevocable Undertaking
12/34/56
EX-10.2
from 8-K 12 pages Institutional Shareholder Irrevocable Undertaking
12/34/56
EX-10.1
from 8-K 14 pages Voting and Support Agreement Article 1 Voting Agreement
12/34/56
EX-10.1
from 10-Q 4 pages July 1, 2024 Najat Khan, PH.D. Re: Employment Offer Letter Dear Najat: Recursion Pharmaceuticals, Inc. (The “Company,” “We,” “US,” or “Our”) Is Truly Excited to Extend You an Offer on the Terms and Conditions in This Letter Agreement (The “Agreement”) and Hope That You Will Be Joining US in Our Mission of Decoding Biology to Radically Improve Lives
12/34/56
EX-10.2
from 10-Q 16 pages Transition Agreement and Release
12/34/56
EX-10.1
from 10-Q 6 pages Advisory Agreement
12/34/56
EX-10.21
from 10-K 83 pages By and Between Bayer AG and Recursion Pharmaceuticals, Inc
12/34/56
EX-10.4
from 10-Q 21 pages Certain Information, Marked by Brackets and Asterisks [***], Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Master Agreement
12/34/56
EX-10.6
from 10-Q 36 pages Open Market Sales Agreement1
12/34/56
EX-10.1
from 10-Q 4 pages May 19, 2023 David Mauro Re: Employment Offer Letter Dear David: Recursion Pharmaceuticals, Inc. (The “Company,” “We,” “US,” or “Our”) Is Truly Excited to Extend You an Offer on the Terms and Conditions in This Letter Agreement (The “Agreement”) and Hope That You Will Be Joining US in Our Mission of Decoding Biology to Radically Improve Lives
12/34/56
EX-10.2
from 8-K 16 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 37 pages Stock Purchase Agreement by and Between Recursion Pharmaceuticals, Inc., and the Purchaser as Set Forth Herein July 11, 2023
12/34/56
EX-10.8
from 10-K 144 pages Material contract
12/34/56
EX-10.3
from 10-K 49 pages Recursion Pharmaceuticals, Inc. 2021 Equity Incentive Plan
12/34/56
EX-10.2
from 8-K 27 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 55 pages Stock Purchase Agreement by and Between Recursion Pharmaceuticals, Inc., and Each of the Purchasers as Set Forth Herein October 24, 2022
12/34/56
EX-10.3
from 10-Q 66 pages Docusign Envelope Id: 6d31cf04-5861-420a-912e-1ebbdebe3fbe Docusign Envelope Id: 6d31cf04-5861-420a-912e-1ebbdebe3fbe Docusign Envelope Id: 6d31cf04-5861-420a-912e-1ebbdebe3fbe Docusign Envelope Id: 6d31cf04-5861-420a-912e-1ebbdebe3fbe Docusign Envelope Id: 6d31cf04-5861-420a-912e-1ebbdebe3fbe Docusign Envelope Id: 6d31cf04-5861-420a-912e-1ebbdebe3fbe Docusign Envelope Id: 6d31cf04-5861-420a-912e-1ebbdebe3fbe Docusign Envelope Id: 6d31cf04-5861-420a-912e-1ebbdebe3fbe Docusign Envelope Id: 6d31cf04-5861-420a-912e-1ebbdebe3fbe Docusign Envelope Id: 6d31cf04-5861-420a-912e-1ebbdebe3fbe Docusign Envelope Id: 6d31cf04-5861-420a-912e-1ebbdebe3fbe Docusign Envelope Id: 6d31cf04-5861-420a-912e-1ebbdebe3fbe Docusign Envelope Id: 6d31cf04-5861-420a-912e-1ebbdebe3fbe Docusign Envelope Id: 6d31cf04-5861-420a-912e-1ebbdebe3fbe Docusign Envelope Id: 6d31cf04-5861-420a-912e-1ebbdebe3fbe Docusign Envelope Id: 6d31cf04-5861-420a-912e-1ebbdebe3fbe Docusign Envelope Id: 6d31cf04-5861-420a-912e-1ebbdebe3fbe Docusign Envelope Id: 6d31cf04-5861-420a-912e-1ebbdebe3fbe Docusign Envelope Id: 6d31cf04-5861-420a-912e-1ebbdebe3fbe Tina Larson Digitally Signed by Donavon Minnis Dn: C=us, E=dminnis@engagecontracting.com, O=engage Contracting Inc, Cn=donavon Minnis Date: 2022.07.13 13:53:41-06'00'
12/34/56
EX-10.2
from 10-Q 9 pages Material contract
12/34/56